Theriva Biologics Inc. Asset Resilience Ratio
Theriva Biologics Inc. asset resilience ratio. Theriva Biologics Inc. (TOVX) has an Asset Resilience Ratio of 33.04% as of September 2011. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TOVX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theriva Biologics Inc. (1999–2000)
Asset resilience ratio of Theriva Biologics Inc. from 1999 to 2000. This chart shows how Theriva Biologics Inc.'s Asset Resilience Ratio has changed over time. Read Theriva Biologics Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theriva Biologics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Theriva Biologics Inc. total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.87 Million | 33.04% |
| Total Liquid Assets | $2.87 Million | 33.04% |
Asset Resilience Insights
- Very High Liquidity: Theriva Biologics Inc. maintains exceptional liquid asset reserves at 33.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theriva Biologics Inc. Industry Peers by Asset Resilience Ratio
Compare Theriva Biologics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Theriva Biologics Inc. Asset Resilience Ratio by Year (1999–2000)
Theriva Biologics Inc. asset resilience ratio by year from 1999 to 2000. The table below shows the annual Asset Resilience Ratio data for Theriva Biologics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2000-12-31 | 6.01% | $327.42K | $5.45 Million | -4.28pp |
| 1999-12-31 | 10.29% | $519.39K | $5.05 Million | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more